LIB-01

LIB-01
Clinical data
Other namesLIB01; DIC-2024; DIC2024; Libiguin
Routes of
administration		Oral[1][2]
Drug classIndirect melanocortin MC4 receptor potentiator

LIB-01, also known as DIC-2024 or as Libiguin, is an indirect melanocortin MC4 receptor potentiator which is under development for the treatment of erectile dysfunction and premature ejaculation.[1][3] It is taken orally.[2]

The drug works by increasing expression of the melanocortin MC4 receptor and of its endogenous agonist in the brain.[3][4] In relation to this, its mechanism of action differs from that of earlier direct melanocortin receptor agonists like bremelanotide.[2][5] As such, the drug is described as a potential first-in-class medication.[2][5] LIB-01 produces non-acute long-lasting pro-erectile effects in rodents and humans, with short-term dosing resulting in gradually increasing improvement that is then sustained for weeks despite cessation of dosing.[3][2][5][6][7] The pro-erectile effects of LIB-01 can be reversed by a melanocortin MC4 receptor antagonist in rodents.[3][4]

LIB-01 is a semisynthetic analogue of alkaloids from Neobeguea mahafalensis root bark such as libiguin A and libiguin B.[7][8] Neobeguea mahafalensis has a long history of traditional use in Madagascar.[7] In 2014, libiguin A and B were discovered via isolation from the roots of the plant and were found to cause "profound enhancement of sexual activity" in rodents.[8][9] This specifically included having very high potency and a remarkably long-lasting duration in increasing mounting behavior in male rodents.[8]

LIB-01 was originated by Uppsala University and is under development by Dicot Pharma.[1] As of December 2025, it is in phase 2 clinical trials for erectile dysfunction and the preclinical research stage of development for premature ejaculation.[1] The mechanism of action of the drug of indirect melanocortin MC4 receptor potentiation was not initially disclosed, but was announced by its developer in December 2025.[3][4] The exact chemical structure of LIB-01 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e "LIB 01". AdisInsight. 26 December 2025. Retrieved 27 January 2026.
  2. ^ a b c d e Padma-Nathan H, Rosen R, Forest C, Holmberg M, Gauffin C (12 August 2024). "(129) Results of a First-In-Human Trial of Lib-01, A Novel, First in Class Potential Oral ed Drug with Unique Pharmacodynamic Properties". The Journal of Sexual Medicine. 21 (Supplement_7) qdae167.127. doi:10.1093/jsxmed/qdae167.127. ISSN 1743-6095. Retrieved 27 January 2026.
  3. ^ a b c d e Foster B (12 January 2026). "A new approach could radically change erectile dysfunction treatment". Drug Discovery News. Retrieved 27 January 2026.
  4. ^ a b c "Dicot Pharma presents new research findings on the mechanism of action of LIB-01". Dicot Pharma. 7 December 2025.
  5. ^ a b c Giuliano F, Padma-Nathan H, Rosen RC, Forest C, Holmberg M, Gauffin C (9 May 2025). "Early Clinical Development Program, Including Results of a First-In-Human Trial of Lib-01, A Novel, First in Class Potential Oral Erectile Dysfunction Drug with Unique Pharmacodynamic Properties". The Journal of Sexual Medicine. 22 (Supplement_2) qdaf077.083. doi:10.1093/jsxmed/qdaf077.083. ISSN 1743-6095. Retrieved 27 January 2026.
  6. ^ Giuliano F, Gorny D, Razanakolona M, Behr-Roussel D, Assaly R, Gauffin C (5 February 2024). "(370) Overview of Nonclinical Studies of LIB-01, a Novel Promising Oral Drug Under Development for Treatment of Erectile Dysfunction". The Journal of Sexual Medicine. 21 (Supplement_1) qdae001.355. doi:10.1093/jsxmed/qdae001.355. ISSN 1743-6095. Retrieved 27 January 2026.
  7. ^ a b c Razanakolona M, Bradesi C, Laurin M, Fugl-Meyer K, Behr-Roussel D, Giuliano F, et al. (1 November 2022). "Prolonged Pro-Erectile Facilitator Effect of Lib-01 in Anesthetized Wistar Rats". The Journal of Sexual Medicine. 19 (Supplement_4): S3. doi:10.1016/j.jsxm.2022.08.082. ISSN 1743-6109. Retrieved 27 January 2026.
  8. ^ a b c Razafimahefa S, Mutulis F, Mutule I, Liepinsh E, Dambrova M, Cirule H, et al. (March 2014). "Libiguins A and B: novel phragmalin limonoids isolated from Neobeguea mahafalensis causing profound enhancement of sexual activity". Planta Medica. 80 (4): 306–314. Bibcode:2014PlMed..80..306R. doi:10.1055/s-0033-1360390. PMID 24549927.
  9. ^ Grigorjeva L, Liepinsh E, Razafimahefa S, Yahorau A, Yahorava S, Rasoanaivo P, et al. (May 2014). "Semisynthesis of libiguin A and its analogues by trans-lactonization of phragmalin". The Journal of Organic Chemistry. 79 (9): 4148–4153. doi:10.1021/jo500318w. PMID 24716657.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.